Nurix Therapeutics (NASDAQ:NRIX) Stock: Insider Houte Hans Van Sells 2,834 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Hans van Houte sold 2,834 shares of the firm’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $26.28, for a total transaction of $74,477.52. Following the sale, the chief financial officer owned 47,514 shares in the company, valued at approximately $1,248,667.92. This represents a 5.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Houte Hans Van also recently made the following trade(s):

• On Tuesday, August 4th, Hans van Houte sold 4,761 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX traded down $1.10 during midday trading on Monday, reaching $25.70. 2,348,532 shares of the stock were exchanged, compared to its average volume of 2,495,734. The stock has a market capitalization of $2.81 billion, a P/E ratio of 11.13 and a beta of 1.82. Nurix Therapeutics, Inc. has a twelve month low of $11.67 and a twelve month high of $28.23. The company has a 50 day simple moving average of $24.98 and a 200 day simple moving average of $20.20.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $5.33. The firm had revenue of $673.06 million during the quarter, compared to analysts’ expectations of $24.35 million. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%. On average, research analysts expect that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current year.

Wall Street Analyst Weigh In

NRIX has been the subject of a number of research analyst reports. UBS Group increased their price target on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Stifel Nicolaus set a $41.00 target price on shares of Nurix Therapeutics in a research report on Tuesday, October 13th. Royal Bank Of Canada dropped their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating for the company in a report on Tuesday, October 13th. Morgan Stanley lifted their price target on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Finally, Robert W. Baird upped their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday, October 13th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.79.

Institutional Trading of Nurix Therapeutics

Several large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Nurix Therapeutics in the 2nd quarter valued at about $212,769,000. Perceptive Advisors LLC increased its holdings in Nurix Therapeutics by 4.4% during the 1st quarter. Perceptive Advisors LLC now owns 3,710,877 shares of the company’s stock worth $57,519,000 after purchasing an additional 155,000 shares during the last quarter. Trails Edge Capital Partners LP acquired a new position in shares of Nurix Therapeutics in the 2nd quarter valued at approximately $38,166,318. Bank of America Corp DE acquired a new position in shares of Nurix Therapeutics in the 2nd quarter valued at approximately $20,429,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Nurix Therapeutics by 81.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 780,696 shares of the company’s stock valued at $12,094,000 after buying an additional 349,710 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.